FrancophonIA/ELRC3.0 huggingface dataset:
English: Common side effects (may affect up to 1 in 10 people) pain, stomach pain difficulty sleeping, abnormal dreams problems with digestion resulting in discomfort after meals, feeling bloated, flatulence rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches other allergic reactions, such as wheezing, swelling or feeling light-headed
Slovenian: flatulenca (napenjanje) - izpuščaji (vključno z rdečimi pikami ali ogrci, včasih z mehurjasto in oteklo kožo), kar je lahko alergijska reakcija, srbečica, sprememba obarvanosti kože, vključujoč temne lise - druge alergijske reakcije, kot so piskanje, otekanje ali omotičnost
English: AUC: ↓ 34% (↓ 41 to ↓ 25) Cmax: ↓ 34% (↓ 41 to ↑ 25) Cmin: ↓ 34% (↓ 43 to ↑ 24) Sofosbuvir:
Slovenian: AUC: ↓ 34 % (↓ 41 do ↓ 25) Cmax: ↓ 34 % (↓ 41 do ↑ 25) Cmin: ↓ 34 % (↓ 43 do ↑ 24)
English: The recommended dose of Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV is:
Slovenian: Priporočeni odmerek zdravila Emtricitabin/dizoproksiltenofovirat Krka za zmanjšanje tveganja za okužbo s HIV je:
English: AUC: ↓ 27% (↓ 35 to ↓ 18) Cmax: ↓ 37% (↓ 48 to ↓ 25) GS-331007
Slovenian: AUC: ↓ 27 % (↓ 35 do ↓ 18) Cmax: ↓ 37 % (↓ 48 do ↓ 25)
English: Talk to your doctor if you have a history of liver disease, including hepatitis.
Slovenian: - Če ste imeli ali imate jetrne bolezni, vključno s hepatitisom, se posvetujte z zdravnikom.
English: Consideration should be given to interrupting use of Emtricitabine/Tenofovir disoproxil Krka in individuals with creatinine clearance decreased to < 60 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L).
Slovenian: Pri posameznikih z zmanjšanjem očistka kreatinina na < 60 ml/min ali z zmanjšanjem serumskega fosfata na < 1,0 mg/dl (0,32 mmol/l) je treba razmisliti o prekinitvi uporabe zdravila Emtricitabin/dizoproksiltenofovirat Krka.
English: Metabolism and nutrition disorders: Very common:
Slovenian: alergijska reakcija Presnovne in prehranske motnje: Zelo pogosto:
English: The adverse reactions considered at least possibly related to treatment with the tenofovir disoproxil and emtricitabine from clinical study and post-marketing experience in HIV-1 infected patients are listed in Table 3, below, by body system organ class and frequency.
Slovenian: Spodaj v preglednici 3 so po organskih sistemih in pogostnosti navedeni neželeni učinki, ki so vsaj možno povezani z zdravljenjem z dizoproksiltenofoviratom in emtricitabinom pri bolnikih s HIV-1 na podlagi kliničnih študij in izkušenj po prihodu zdravila na tržišče.
English: Antimycobacterials Rifampicin/Tenofovir disoproxil
Slovenian: Zdravila za zdravljenje okužb z mikobakterijami rifampicin/ dizoproksiltenofovirat tenofovir:
English: - HIV renal educational brochure - HIV pediatric renal educational brochure - PrEP educational brochure for prescribers entitled ‘Important Safety Information for
Slovenian: - Izobraževalno gradivo o virusu HIV in delovanju ledvic; - izobraževalno gradivo glede ledvic pri HIV za pediatrične bolnike; - izobraževalno gradivo glede ledvic pri HIV; - izobraževalno gradivo PrEP za predpisujoče zdravnike z naslovom »Pomembne varnostne informacije za predpisujoče zdravnike glede zdravila Emtricitabin/dizoproksiltenofovirat Krka pri indikaciji zaščite pred izpostavitvijo (PrEP)«; - kontrolni seznam PrEP za predpisujoče zdravnike; - izobraževalno gradivo PrEP za ogrožene posameznike z naslovom »Pomembne informacije glede zdravila Emtricitabin/dizoproksiltenofovirat Krka za zmanjšanje tveganja okužbe s humanim imunodeficientnim virusom (HIV)«; - opozorila kartica PrEP.
English: The effectiveness of Emtricitabine/Tenofovir disoproxil Krka in reducing the risk of acquiring HIV-1 is strongly correlated with adherence as demonstrated by measurable drug levels in blood (see section 5.1).
Slovenian: HIV-1 je v veliki meri odvisna od adherence, ki jo lahko preverimo z merljivenjem koncentracije učinkovin v krvi (glejte poglavje 5.1).
English: Placebo Tenofovir disoproxil 245 mg +Emtricitabine/tenofovir disoproxil
Slovenian: Dizoproksiltenofovir at 245 mg + Emtricitabi n/dizoproksiltenofovi rat
English: Adefovir dipivoxil and Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly (see section 4.4).
Slovenian: Dipivoksiladefovirata in zdravila Emtricitabin/dizoproksiltenofovirat Krka se ne sme uporabljati sočasno (glejte poglavje 4.4).
English: In a study of 498 men, the mean changes from baseline to week 24 in BMD ranged from - 0.4% to - 1.0% across hip, spine, femoral neck and trochanter in men who received daily emtricitabine/tenofovir disoproxil prophylaxis (n = 247) vs. placebo (n = 251).
Slovenian: Pri moških, ki so vsak dan prejemali emtricitabin/dizoproksiltenofovirat za zaščito (n = 247) v primerjavi s placebom (n = 251) so bile povprečne spremembe MKG od izhodišča do 24. tedna na kolkih, hrbtenici, vratu in trohantru stegnenice od -0,4 % do -1,0 %.
English: Do not breast-feed during treatment with Emtricitabine/Tenofovir disoproxil Krka.
Slovenian: - Med zdravljenjem z zdravilom Emtricitabin/dizoproksiltenofovirat Krka ne dojite.
English: Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with adefovir dipivoxil.
Slovenian: Zdravilo Emtricitabin/dizoproksiltenofovirat Krka se ne sme sočasno uporabljati z dipivoksiladefoviratom.
English: AUC: ↑ 96% (↑ 74 to ↑ 121) Cmax: ↑ 68% (↑ 54 to ↑ 84) Cmin: ↑ 118% (↑ 91 to ↑ 150) Sofosbuvir:
Slovenian: AUC: ↑ 96 % (↑ 74 do ↑ 121) Cmax: ↑ 68 % (↑ 54 do ↑ 84) Cmin: ↑ 118 % (↑ 91 do ↑ 150)
English: HIV-1 RNA < 50 copies/mL (TLOVR)
Slovenian: RNA < 50 kopij/ml (TLOVR) Vrednost p Razlika v % (95 % IZ)
English: What Emtricitabine/Tenofovir disoproxil Krka contains - The active substances are emtricitabine and tenofovir disoproxil.
Slovenian: Kaj vsebuje zdravilo Emtricitabin/dizoproksiltenofovirat Krka - Učinkovini sta emtricitabin in dizoproksiltenofovirat.
English: UAB KRKA Lietuva Tel: + 370 5 236 27 40
Slovenian: Tel: + 370 5 236 27 40
English: Lopinavir/Ritonavir/Emtricitabine Interaction not studied.
Slovenian: lopinavir/ritonavir/emtricita bin
English: Efficacy was strongly correlated with adherence as assessed by detection of plasma or intracellular drug levels and was higher among substudy participants who received active adherence counselling and as show in Table 10.
Slovenian: Višja je bila pri sodelujočih v podštudiji, ki so prejemali aktivno svetovanje glede adherence, kot je prikazana v preglednici 10.
English: In study GS-US-104-0352, 97 treatment-experienced patients 2 to < 12 years of age with stable, virologic suppression on stavudine- or zidovudine-containing regimens were randomised to either replace stavudine or zidovudine with tenofovir disoproxil (n = 48) or continue on their original regimen (n = 49) for 48 weeks.
Slovenian: virološko supresijo z režimom, ki je vseboval stavudin ali zidovudin, randomizirali v skupino, v kateri so stavudin ali zidovudin nadomestili z dizoproksiltenofoviratom (n = 48) ali nadaljevali s prvotnim režimom (n = 49) 48 tednov.
English: Cmax: ↓ 19% (↓ 40 to ↑ 10) GS-331007
Slovenian: Cmax: ↓ 19 % (↓ 40 do ↑ 10)
English: BMD Z scores declined by -0.012 for lumbar spine and by -0.338 for total body in the 64 subjects who were treated with tenofovir disoproxil for 96 weeks.
Slovenian: Z-vrednosti MGK so se pri 64 osebah, ki so se 96 tednov zdravile z dizoproksiltenofoviratom, zmanjšale za -0,012 za ledveno hrbtenico in za -0,338 za celo telo.
English: - Reminder of the key safety information regarding the use of Emtricitabine/Tenofovir disoproxil Krka for PrEP in adults and adolescents - Reminder of factors to help identify individuals at high risk of acquiring HIV 1 - Reminder on the risk of development of HIV 1 drug resistance in undiagnosed HIV 1
Slovenian: Emtricitabin/dizoproksiltenofovirat Krka za PrEP za odrasle in mladostnike; - opozorilo na dejavnike, ki pomagajo določiti posameznike z visokim tveganjem za HIV-1; - opozorilo na tveganje za razvoj rezistence zdravila proti HIV-1 pri posameznikih s HIV-1, ki še nimajo postavljene diagnoze; - nudi varnostne informacije glede adherence, testiranja za HIV, stanja ledvic, kosti in HBV.
English: A single 245 mg dose of tenofovir disoproxil was administered to non-HIV infected subjects with varying degrees of hepatic impairment defined according to Child-Pugh-Turcotte (CPT) classification.
Slovenian: Osebam brez okužbe s HIV, ki so imele različne stopnje jetrne okvare po klasifikaciji Child-PughTurcotte (CPT), so dali enkratni 245-mg odmerek dizoproksiltenofovirata.
English: HIV-1 RNA < 400 copies/mL (TLOVR)
Slovenian: RNA < 400 kopij/ml (TLOVR) Vrednost p Razlika v % (95 % IZ)
English: Cmin: ↑ 48% (↑ 34 to ↑ 63) Emtricitabine:
Slovenian: Cmin: ↑ 48 % (↑ 34 do ↑ 63)
English: Age (Yrs), Mean (SD)
Slovenian: Starost (leta), povprečje (SD) Rasa, N (%)
English: FTC/tenofovir disoproxil Group
Slovenian: FTC/dizoproksiltenofovi rat
English: Darunavir/Ritonavir/Tenofovir disoproxil (300 mg q.d./100 mg q.d./245 mg q.d.)
Slovenian: darunavir/ritonavir/ dizoproksiltenofovirat (300 mg enkrat dnevno/100 mg enkrat dnevno/245 mg enkrat dnevno)
English: Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly (see section 4.4).
Slovenian: Lamivudina in zdravila Emtricitabin/dizoproksiltenofovirat Krka se ne sme uporabljati sočasno (glejte poglavje 4.4).
English: Cmax: ↑ 79% (↑ 56 to ↑ 104) Cmin: ↑ 163% (↑ 137 to ↑ 197)
Slovenian: AUC: ↑ 98 % (↑ 77 do ↑ 123) Cmax: ↑ 79 % (↑ 56 to ↑ 104) Cmin: ↑ 163 % (↑ 137 do ↑ 197)
English: Cmin: ↑ 45% (↑ 27 to ↑ 64) Emtricitabine:
Slovenian: Cmin: ↑ 45 % (↑ 27 do ↑ 64)
English: Cmin: ↑ 63% (↑ 45 to ↑ 84) Ritonavir:
Slovenian: Cmin: ↑ 63 % (↑ 45 do ↑ 84)
English: Relative Risk Reduction (2
Slovenian: Relativno zmanjšanje tveganja (95odstotni IZ)
English: Mean changes at week 48 (end of randomised phase) were 0.032 and 0.087 in lumbar spine BMD Z score, and -0.184 and -0.027 in total body BMD Z score for the tenofovir disoproxil and stavudine or zidovudine groups, respectively.
Slovenian: MGK ledvene hrbtenice in -0,184 oz. -0,027 za Z-vrednost MGK za celo telo za skupino z dizoproksiltenofoviratom in skupino s stavudinom ali zidovudinom.
English: In patients who received treatment with tenofovir disoproxil, or stavudine or zidovudine, mean lumbar spine BMD Z score was -1.034 and -0.498, and mean total body BMD Z-score was -0.471 and -0.386, respectively, at baseline.
Slovenian: ledvene hrbtenice -1,034 oz. -0,498 in povprečna Z-vrednost MGK za celo telo -0,471 oz. -0,386.
English: Lopinavir/Ritonavir/Tenofovir disoproxil (400 mg b.i.d./100 mg b.i.d/245 mg q.d.)
Slovenian: lopinavir/ritonavir/ dizoproksiltenofovirat (400 mg dvakrat dnevno/100 mg dvakrat dnevno/245 mg enkrat dnevno)
English: expected to decrease plasma concentrations of velpatasvir.
Slovenian: Pri sočasni uporabi sofosbuvirja/velpatasvirja in efavirenza se pričakuje zmanjšanje koncentracije velpatasvirja v plazmi.
English: How to store Emtricitabine/Tenofovir disoproxil Krka
Slovenian: Kako jemati zdravilo Emtricitabin/dizoproksiltenofovirat Krka
English: Other effects in children Children given emtricitabine very commonly experienced changes in skin colour including darkening of the skin in patches Children commonly experienced low red blood cell count (anaemia) - this may cause the child to be tired or breathless → If you notice any of these symptoms tell your doctor.
Slovenian: Drugi učinki pri otrocih Otroci, ki so dobivali emtricitabin, so imeli zelo pogosto spremembe obarvanosti kože, vključno s temno obarvanimi kožnimi lisami.
English: Rare side effects
Slovenian: Učinki na ledvice
English: Cmax: ↓ 23% (↓ 30 to ↑ 16) Efavirenz:
Slovenian: Cmax: ↓ 23 % (↓ 30 do ↑ 16)
English: Emtricitabine/Tenofovir disoproxil Krka
Slovenian: Emtricitabin/dizoproksiltenofovirat Krka
English: Tenofovir disoproxil Group
Slovenian: Skupina dizoproksiltenofovirat
English: Didanosine/Tenofovir disoproxil
Slovenian: didanozin/dizoproksiltenofo virat
English: Lamivudine/Tenofovir disoproxil Lamivudine: AUC: ↓ 3% (↓ 8% to ↑ 15) Cmax: ↓ 24% (↓ 44 to ↓ 12) Cmin: NC
Slovenian: AUC: ↓ 3 % (↓ 8 % do ↑ 15) Cmax: ↓ 24 % (↓ 44 do ↓ 12) Cmin: n/i tenofovir:
English: asthenia
Slovenian: ZDRAVILOM
English: It is important not to stop taking Emtricitabine/Tenofovir disoproxil Krka without talking to your doctor: see section 3, Do not stop taking Emtricitabine/Tenofovir disoproxil Krka.
Slovenian: Če imate hepatitis B, obstaja resno tveganje za jetrne težave, ko prenehate jemati zdravilo Emtricitabin/dizoproksiltenofovirat Krka, ne glede na to, ali imate HIV ali ne. Pomembno je, da zdravila Emtricitabin/dizoproksiltenofovirat Krka ne prenehate jemati, ne da bi se posvetovali z zdravnikom: glejte poglavje 3, Ne prenehajte jemati zdravila Emtricitabin/dizoproksiltenofovirat Krka.
English: Lamivudine and
Slovenian: rabdomioliza
English: Pack sizes: 28 and 84 film-coated tablets.
Slovenian: OPA/Al/PE+DES - aluminijska folija Velikost pakiranj: 28 in 84 filmsko obloženih tablet
English: For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Slovenian: Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom: België/Belgique/Belgien KRKA Belgium, SA.
English: Adefovir dipivoxil: AUC: ↓ 11% (↓ 14 to ↓ 7) Cmax: ↓ 7% (↓ 13 to ↓ 0) Cmin: NC
Slovenian: ZDRAVILA ZA ZDRAVLJENJE OKUŽB Protivirusna zdravila za zdravljenje hepatitisa B (HBV) dipivoksiladefovirat/ dizoproksiltenofovirat dipivoksiladefovirat: AUC: ↓ 11 % (↓ 14 do ↓ 7) Cmax: ↓ 7 % (↓ 13 do ↓ 0) Cmin: n/i tenofovir:
English: Increased plasma concentrations of tenofovir resulting from coadministration of tenofovir disoproxil, ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Slovenian: Povečane koncentracije tenofovirja v plazmi zaradi sočasne uporabe dizoproksiltenofovirata, sofosbuvirja/velpatasvirja in atazanavirja/ritonavirja lahko povečajo neželene reakcije, povezane z dizoproksiltenofoviratom, vključno z ledvičnimi boleznimi.
English: Film coating
Slovenian: filmsko obložena tableta
English: Cmax:↔ Cmin: N/A
Slovenian: Cmax: ↔ Cmin: ↔
English: Voxilaprevir: AUC: ↑ 143% Cmax:↑ 72% Cmin: ↑ 300%
Slovenian: AUC: ↑ 37 % Cmax: ↑ 34 % Cmin: ↑ 29 %
English: You must be HIV negative before you start to take Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV.
Slovenian: - Pred začetkom jemanja zdravila Emtricitabin/dizoproksiltenofovirat Krka za zmanjšanje tveganja za okužbo z virusom HIV-1, morate biti HIV negativni.
English: Increased plasma concentrations of tenofovir resulting from coadministration of tenofovir disoproxil, ledipasvir/sofosbuvir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Slovenian: Povečane koncentracije tenofovirja v plazmi zaradi sočasnega dajanja dizoproksiltenofovirata, sofosbuvirja/velpatasvirja/voksilapr evirja in darunavirja/ritonavirja lahko povečajo neželene učinke, povezane z dizoproksiltenofoviratom, vključno z motnjami delovanja ledvic.
English: Cmin: ↑ 42% (↑ 34 to ↑ 49) Atazanavir:
Slovenian: Cmin: ↑ 42 % (↑ 34 do ↑ 49)
English: Tablet core
Slovenian: Za plastenko
English: Detection Versus No Detection of Tenofovir
Slovenian: Ocena tveganja za zaščito pred HIV-1: zaznavanje v primerjavi z nezaznavanjem tenofovirja
English: Cmax: ↓ 41% (↓ 51 to ↓ 29)
Slovenian: AUC: ↓ 29 % (↓ 36 do ↓ 22) Cmax: ↓ 41% (↓ 51 do ↓ 29)
English: Section 4.4 “Special warnings and precautions for use” “The maximum recommended daily dose should not be exceeded (see section 4.2).”
Slovenian: Poglavje 4.4 „Posebna opozorila in previdnostni ukrepi“ „Največji priporočeni dnevni odmerek se ne sme preseči (glejte poglavje 4.2).“
English: Section 4.3 “Contraindications” “Somatropin must not be used when there is any evidence of activity of a tumour.
Slovenian: Poglavje 4.3 „Kontraindikacije“ „Somatropin se ne sme uporabljati, če obstaja kakršen koli dokaz o aktivnosti tumorja.
English: Before you use <(Invented) name of the product> Do not use <(Invented) name of the product> and tell your doctor if you have an active tumour (cancer).
Slovenian: Pred uporabo zdravila <(Izmišljeno) ime zdravila> Ne uporabljajte zdravila <(Izmišljeno) ime zdravila> in o tem obvestite svojega zdravnika, če imate aktiven tumor (raka).
English: Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy.
Slovenian: Intrakranialni tumorji morajo biti neaktivni, zdravljenje tumorjev pa mora biti končano pred začetkom zdravljenja z rastnim hormonom.
English: Tumours must be inactive and you must have finished your anti-tumour treatment before you start your treatment with <(Invented) name of the product>.
Slovenian: Tumorji morajo biti neaktivni in njihovo zdravljenje mora biti končano pred začetkom zdravljenja z zdravilom <(Izmišljeno) ime zdravila>.
English: Amendments to the Summary of Product Characteristics and Package Leaflet for all somatropin medicinal products:
Slovenian: Dopolnilo povzetka glavnih značilnosti zdravila in navodila za uporabo pri vseh zdravilih, ki vsebujejo somatropin:
English: Treatment should be discontinued if there is evidence of tumour growth.”
Slovenian: Ob kakršnem koli dokazu o rasti tumorja je treba zdravljenje prekiniti.“
English: Amendments to the Summaries of Product Characteristics and Package Leaflets
Slovenian: Priloga III Dopolnilo povzetkov glavnih značilnosti zdravila in navodil za uporabo
English: Non-clinical data on the cold compound (non-radioactive lutetium (
Slovenian: Neklinični podatki za hladno spojino (neradioaktivni lutecijev (
English: People who need extra assistance
Slovenian: Ljudje, ki potrebujejo dodatno pomoč
English: This happens in many patients and is frequently temporary.
Slovenian: To se zgodi pri mnogih bolnikih in je pogosto začasno.
English: 4 hours
Slovenian: 4 ur
English: It is absolutely necessary to use toilet paper each time.
Slovenian: Nujno potrebno je vsakič uporabiti toaletni papir.
English: This is the only parameter to determine the procedure completion.
Slovenian: To je edini parameter za določitev konca postopka.
English: 20 to 30 minutes
Slovenian: 20-30 minut
English: However, you must adhere to the following rules to maximize the safety of other persons.
Slovenian: Kljub temu pa morate upoštevati naslednja pravila, da bi zagotovili kar največjo varnost drugih oseb.
English: A member of the hospital staff will tell you how and when to get rid of these trash bags.
Slovenian: Član bolnišničnega osebja vam bo povedal, kako in kdaj se znebiti teh vrečk za smeti.
English: Recommended measures in case of extravasation
Slovenian: Priporočeni ukrepi v primeru ekstravazacije
English: Clinical experience has not identified differences in responses between the elderly and younger patients.
Slovenian: Klinične izkušnje niso pokazale razlik v odzivu pri starejših in mlajših bolnikih.
English: The following checking should be carried out every week, for the next 10 weeks:
Slovenian: Vsak teden v naslednjih 10 tednih je treba izvesti naslednje preiskave:
English: This includes the handling of any materials possibly contaminated with urine.
Slovenian: To vključuje ravnanje z vsakršnimi materiali, ki bi lahko bili kontaminirani z urinom.
English: The average beta energy is approximately 0.13 MeV.
Slovenian: Povprečna energija beta je približno 0,13 MeV.
English: This should be taken into consideration when using the following information.
Slovenian: Pri uporabi naslednjih informacij je treba to upoštevati.
English: The patient guide shall contain the following key elements:
Slovenian: Vodnik za bolnike mora vsebovati naslednje ključne elemente:
English: Symptoms, especially inflammation and/or pain, should be treated.
Slovenian: Simptome, zlasti vnetje in/ali bolečine, je treba zdraviti.
English: The safety and efficacy of this medicine has not yet been established in children and adolescents under 18 years of age.
Slovenian: Varnost in učinkovitost tega zdravila pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
English: The doctor will inform you when you can leave the controlled area or the hospital.
Slovenian: Zdravnik vas bo obvestil o tem, kdaj lahko zapustite nadzorovano območje ali bolnišnico.
English: These rules are the result of many years of experience in the use of radioactivity in medicine, and they include recommendations issued by international organizations.
Slovenian: Ta pravila so rezultat dolgoletnih izkušenj pri uporabi radioaktivnih snovi v medicini in vključujejo priporočila, ki so jih izdale mednarodne organizacije.
English: Mutagenicity studies und long-term carcinogenicity studies have not been carried out.
Slovenian: Študije mutagenosti in dolgoročne karcinogenosti niso bile izvedene.
English: However, in rare cases the decrease in blood cells may be long standing and/or permanent.
Slovenian: V redkih primerih pa je lahko znižanje števila krvnih celic dolgotrajno in/ali stalno.
English: Most patients were Dutch (811) with the remaining (403) residents of various European and non-European countries.
Slovenian: Večina bolnikov je bilo Nizozemcev (811), ostali (403) pa so bili prebivalci različnih evropskih in neevropskih držav.
English: N: number of patients, CI: confidence interval.
Slovenian: N: število bolnikov, CI: interval zaupanja.
English: It is helpful to estimate the effective dose that was applied.
Slovenian: Koristno je oceniti učinkoviti uporabljeni odmerek.
English: 1.5 L to 2.2 L
Slovenian: 1,5-2,2 l
English: 72 hours from the date and time of calibration.
Slovenian: 72 ur od datuma in ure umerjanja.
English: The surface dose rates and the accumulated dose depend on many factors.
Slovenian: Stopnja površinskega odmerka in akumuliranega odmerka je odvisna od mnogih dejavnikov.
English: It is also important to wash your hands to avoid contaminating the door handles.
Slovenian: Prav tako je pomembno, da si umijete roke in tako preprečite onesnaženje kljuke na vratih.
English: Temporarily discontinue the treatment.
Slovenian: Začasno prekinite zdravljenje.
English: Follow your doctor's advice on how much fluid to drink.
Slovenian: Upoštevajte zdravnikove napotke o tem, koliko tekočine morate piti.
English: • Additional risk minimisation measures
Slovenian: • Dodatni ukrepi za zmanjševanje tveganja
English: The mean age of patients enrolled in the study was 58.4 years.
Slovenian: Povprečna starost bolnikov, vključenih v študijo, je bila 58,4 leta.
English: The extravasation area must be monitored until the patient is discharged from the hospital.
Slovenian: Območje za ekstravazacijo je treba spremljati, dokler ni bolnik odpuščen iz bolnišnice.
English: Considering current knowledge and experience in this field and the physical and pharmaceutical properties of the medicine, it is estimated that the health risks to your family members and the general public are low.
Slovenian: Glede na trenutno znanje in izkušnje na tem področju in glede na fizikalne in farmacevtske lastnosti zdravila se ocenjuje, da so tveganja za zdravje vaših družinskih članov in širše javnosti nizka.
English: This preparation is likely to result in a relatively high radiation dose to most patients.
Slovenian: Ta pripravek bo verjetno povzročil relativno visoke odmerke sevanja večini bolnikov.
English: The use of television monitor systems to monitor the patients is recommended.
Slovenian: Priporočljiva je uporaba televizijskih sistemov za spremljanje bolnikov.
English: • Brief introduction to the treatment and the administration procedure
Slovenian: • kratek uvod v zdravljenje in postopek aplikacije;
English: The administration of 7,400 MBq may result in significant environmental hazard.
Slovenian: Apliciranje 7.400 MBq lahko povzroči pomembno nevarnost za okolje.
English: Low gamma energy is also emitted, for instance at 113 keV (6.2%) and 208 keV (11%).
Slovenian: Oddaja tudi nizko vrednost energije gama, na primer pri 113 keV (6,2 %) in 208 keV (11 %).